Category: Announcements
-
Cure HHT Wins Inaugural Prix Galien Patient First Award in Honor of Michael J. Fox
Recognition in the Patient-Led Initiatives category honors an approach to progress built around patients, partnerships, and shared purpose. Cure HHT has won the inaugural…
-
Honoring the People Who Built the HHT Field—and Those Building What Comes Next | Awards
At every scientific conference, there are moments when we look forward: toward the next question, the next clinical trial, the next discovery that could…
-
RougeTx Launches with HHT as Lead Therapeutic Program
RougeTx, a new biotechnology company focused on vascular disease, has launched with $58 million in Series A financing to advance RTX-001, an investigational treatment…
-
Tectonic Reports Early Safety Data for TX2100: What It Means for HHT Research
The hereditary hemorrhagic telangiectasia (HHT) treatment landscape continues to grow. On September 29, Tectonic Therapeutic announced early clinical results for TX2100, an investigational therapy…